224 related articles for article (PubMed ID: 12813467)
41. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
Yu K; Toral-Barza L; Discafani C; Zhang WG; Skotnicki J; Frost P; Gibbons JJ
Endocr Relat Cancer; 2001 Sep; 8(3):249-58. PubMed ID: 11566616
[TBL] [Abstract][Full Text] [Related]
42. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Hui L; Rodrik V; Pielak RM; Knirr S; Zheng Y; Foster DA
J Biol Chem; 2005 Oct; 280(43):35829-35. PubMed ID: 16109716
[TBL] [Abstract][Full Text] [Related]
43. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
Yang X; Lin J; Gong Y; Ma H; Shuai X; Zhou R; Guo Y; Shan Q; He G
Hematol Oncol; 2012 Sep; 30(3):123-30. PubMed ID: 21898527
[TBL] [Abstract][Full Text] [Related]
44. SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line.
Lingrand M; Lalonde S; Jutras-Carignan A; Bergeron KF; Rassart E; Mounier C
Breast Cancer; 2020 Jul; 27(4):594-606. PubMed ID: 31993937
[TBL] [Abstract][Full Text] [Related]
45. Evidence for cell cycle-dependent, rapamycin-resistant phosphorylation of ribosomal protein S6 at S240/244.
Rosner M; Hengstschläger M
Amino Acids; 2010 Nov; 39(5):1487-92. PubMed ID: 20464435
[TBL] [Abstract][Full Text] [Related]
46. A low molecular weight factor from dividing cells activates phospholipase D in caveolin-enriched membrane microdomains.
Bychenok S; Foster DA
Arch Biochem Biophys; 2000 May; 377(1):139-45. PubMed ID: 10775453
[TBL] [Abstract][Full Text] [Related]
47. Reciprocal regulation of AMP-activated protein kinase and phospholipase D.
Mukhopadhyay S; Saqcena M; Chatterjee A; Garcia A; Frias MA; Foster DA
J Biol Chem; 2015 Mar; 290(11):6986-93. PubMed ID: 25632961
[TBL] [Abstract][Full Text] [Related]
48. Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).
Foster DA; Salloum D; Menon D; Frias MA
J Biol Chem; 2014 Aug; 289(33):22583-22588. PubMed ID: 24990952
[TBL] [Abstract][Full Text] [Related]
49. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells.
Rouf MA; Vural I; Renoir JM; Hincal AA
J Liposome Res; 2009; 19(4):322-31. PubMed ID: 19863167
[TBL] [Abstract][Full Text] [Related]
50. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells.
Rodrik V; Gomes E; Hui L; Rockwell P; Foster DA
FEBS Lett; 2006 Oct; 580(24):5647-52. PubMed ID: 16996503
[TBL] [Abstract][Full Text] [Related]
51. Ethanol inhibits astroglial cell proliferation by disruption of phospholipase D-mediated signaling.
Kötter K; Klein J
J Neurochem; 1999 Dec; 73(6):2517-23. PubMed ID: 10582613
[TBL] [Abstract][Full Text] [Related]
52. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.
Foster DA
Biochim Biophys Acta; 2009 Sep; 1791(9):949-55. PubMed ID: 19264150
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds.
Brunner G; Zalkow L; Burgess E; Rifkin DB; Wilson EL; Gruszecka-Kowalik E; Powis G
Anticancer Res; 1996; 16(5A):2513-6. PubMed ID: 8917344
[TBL] [Abstract][Full Text] [Related]
54. A Repertoire of MicroRNAs Regulates Cancer Cell Starvation by Targeting Phospholipase D in a Feedback Loop That Operates Maximally in Cancer Cells.
Fite K; Elkhadragy L; Gomez-Cambronero J
Mol Cell Biol; 2016 Jan; 36(7):1078-89. PubMed ID: 26787840
[TBL] [Abstract][Full Text] [Related]
55. Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells.
Diaz-Aragon R; Ramirez-Ricardo J; Cortes-Reynosa P; Simoni-Nieves A; Gomez-Quiroz LE; Perez Salazar E
Mol Cell Biochem; 2019 Jul; 457(1-2):119-132. PubMed ID: 30877512
[TBL] [Abstract][Full Text] [Related]
56. Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.
El Osta M; Liu M; Adada M; Senkal CE; Idkowiak-Baldys J; Obeid LM; Clarke CJ; Hannun YA
FASEB J; 2014 Jan; 28(1):495-505. PubMed ID: 24121461
[TBL] [Abstract][Full Text] [Related]
57. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells.
Zhong M; Shen Y; Zheng Y; Joseph T; Jackson D; Foster DA
Biochem Biophys Res Commun; 2003 Mar; 302(3):615-9. PubMed ID: 12615079
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Grosso SH; Katayama ML; Roela RA; Nonogaki S; Soares FA; Brentani H; Lima L; Folgueira MA; Waitzberg AF; Pasini FS; Góes JC; Brentani MM
Cell Tissue Res; 2013 Jun; 352(3):671-84. PubMed ID: 23636418
[TBL] [Abstract][Full Text] [Related]
59. Phosphatidic acid is a leukocyte chemoattractant that acts through S6 kinase signaling.
Frondorf K; Henkels KM; Frohman MA; Gomez-Cambronero J
J Biol Chem; 2010 May; 285(21):15837-47. PubMed ID: 20304930
[TBL] [Abstract][Full Text] [Related]
60. Mammalian target of rapamycin (mTOR) and S6 kinase down-regulate phospholipase D2 basal expression and function.
Tabatabaian F; Dougherty K; Di Fulvio M; Gomez-Cambronero J
J Biol Chem; 2010 Jun; 285(25):18991-9001. PubMed ID: 20410302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
